Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NELSON M HANDAL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Child & Adolescent Psychiatry

NPI
1154471548
CMS profile
52801
Location
DOTHAN, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$9,235.45

97 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,400.00 1
Debt forgiveness $2,808.76 1
Food and Beverage $1,987.82 93
Travel and Lodging $27.00 1
Education $11.87 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NELSON M HANDAL

NPI 1154471548 · CMS profile ID 52801

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Child & Adolescent Psychiatry

DOTHAN, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154471548?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NELSON M HANDAL, NPI 1154471548, CMS profile ID 52801. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154471548?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NELSON M HANDAL, NPI 1154471548, CMS profile ID 52801. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154471548?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NELSON M HANDAL, NPI 1154471548, CMS profile ID 52801, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1154471548?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

97 matching records · $9,235.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 97 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–97 of 97.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Tris Pharma Inc $13.2806/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147229759 CMS
Tris Pharma Inc $15.7506/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147229765 CMS
Almatica Pharma LLC $22.7706/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137565016 CMS
Alkermes, Inc. $18.8306/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120511549 CMS
Janssen Pharmaceuticals, Inc $20.3706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077905211 CMS
Vanda Pharmaceuticals Inc. $12.3506/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133905437 CMS
Otsuka America Pharmaceutical, Inc. $14.8906/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118904677 CMS
Corium, LLC $24.5305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100084516 CMS
IRONSHORE PHARMACEUTICALS INC. $19.2405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146269824 CMS
ABBVIE INC. $12.7005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103873143 CMS
Brainsway USA INC $26.2305/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125501675 CMS
ABBVIE INC. $2.2705/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103873141 CMS
Almatica Pharma LLC $20.4905/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137565012 CMS
Tris Pharma Inc $17.8005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147229755 CMS
IRONSHORE PHARMACEUTICALS INC. $18.3005/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146269788 CMS
Corium, LLC $4,400.0005/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100221179 CMS
Corium, LLC $21.0205/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100094293 CMS
Janssen Pharmaceuticals, Inc $24.1204/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077904863 CMS
Janssen Pharmaceuticals, Inc $17.6804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077905441 CMS
Corium, LLC $17.2404/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100106300 CMS
Almatica Pharma LLC $17.7104/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137565008 CMS
Corium, LLC $40.1804/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100221345 CMS
Corium, LLC $47.0504/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100221347 CMS
Corium, LLC $27.0004/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100221349 CMS
Teva Pharmaceuticals USA, Inc. $17.0204/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151669637 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $14.5104/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143238765 CMS
ABBVIE INC. $17.2004/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103873139 CMS
ABBVIE INC. $4.4204/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103873137 CMS
Janssen Pharmaceuticals, Inc $20.5804/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077904873 CMS
ABBVIE INC. $11.6204/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103873135 CMS
Teva Pharmaceuticals USA, Inc. $20.3604/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151669633 CMS
Tris Pharma Inc $15.9104/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147229767 CMS
Almatica Pharma LLC $17.7103/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137565003 CMS
Janssen Pharmaceuticals, Inc $22.0803/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077904995 CMS
Otsuka America Pharmaceutical, Inc. $15.0703/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118904675 CMS
ABBVIE INC. $19.3203/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103873133 CMS
Janssen Pharmaceuticals, Inc $20.5603/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077905335 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2602/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137569943 CMS
Janssen Pharmaceuticals, Inc $24.4302/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077905385 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $21.7402/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143238762 CMS
IRONSHORE PHARMACEUTICALS INC. $16.5402/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146269672 CMS
Otsuka America Pharmaceutical, Inc. $17.8002/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118904673 CMS
ABBVIE INC. $14.1701/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103873131 CMS
Janssen Pharmaceuticals, Inc $24.2301/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077904879 CMS
Janssen Pharmaceuticals, Inc $15.4001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077905399 CMS
Corium, LLC $25.6501/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100082234 CMS
Tris Pharma Inc $19.7301/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147229757 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,508.91 74
PY2020 $219.05 12
PY2021 $10,169.92 70
PY2022 $17,181.21 90
PY2023 $25,917.06 132
PY2024 $9,235.45 97
PY2025 $3,970.04 91

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,860.00 13
PY2025 Principal investigator $220,963.61 138
PY2024 Principal investigator $389,146.93 36
PY2023 Principal investigator $148,157.10 29
PY2022 Principal investigator $389,428.09 87
PY2021 Principal investigator $255,145.12 58
PY2020 Recipient $1,772.14 7
PY2020 Principal investigator $502,226.52 105
PY2019 Principal investigator $536,140.88 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

151 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,402.52 12/31/2025 Non-covered Recipient Entity
HARMONEX NEUROSCIENCE RESEARCH
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202532911
Principal investigator 1 ABBVIE INC. $1,699.68 12/31/2025 Non-covered Recipient Entity
HARMONEX NEUROSCIENCE RESEARCH
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder No dispute reported 06/30/2026 1202532915
Principal investigator 1 Alkermes, Inc. $1,729.38 12/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208621002
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,000.00 12/19/2025 Non-covered Recipient Entity
HARMONEX INC
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232947246
Recipient ABBVIE INC. $65.25 12/10/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398736
Recipient ABBVIE INC. $27.00 12/10/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398739
Recipient ABBVIE INC. $70.00 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398709
Recipient ABBVIE INC. $60.00 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398711
Recipient ABBVIE INC. $24.99 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398716
Recipient ABBVIE INC. $924.54 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398720
Recipient ABBVIE INC. $25.00 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398723
Recipient ABBVIE INC. $175.48 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398728
Recipient ABBVIE INC. $24.65 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398733
Recipient ABBVIE INC. $70.00 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398692
Recipient ABBVIE INC. $132.85 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398696
Recipient ABBVIE INC. $24.99 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398700
Recipient ABBVIE INC. $235.25 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202398704
Principal investigator 1 ABBVIE INC. $11,032.00 12/04/2025 Non-covered Recipient Entity
HARMONEX INC
A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Major Depressive Disorder No dispute reported 06/30/2026 1202527672
Principal investigator 1 ABBVIE INC. $8,834.70 12/04/2025 Non-covered Recipient Entity
HARMONEX INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202527674
Principal investigator 1 Vanda Pharmaceuticals Inc. $4,491.25 12/03/2025 Non-covered Recipient Entity
HARMONEX INC
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232947108
Principal investigator 1 ABBVIE INC. $3,534.70 11/05/2025 Non-covered Recipient Entity
HARMONEX INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202522775
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,035.00 10/22/2025 Non-covered Recipient Entity
HARMONEX INC
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232946734
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,000.00 10/17/2025 Non-covered Recipient Entity
HARMONEX INC
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA No dispute reported 06/30/2026 1232946597
Principal investigator 1 Alkermes, Inc. $1,608.75 09/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620662
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,250.00 09/04/2025 Non-covered Recipient Entity
HARMONEX INC
SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS No dispute reported 06/30/2026 1232946317
Principal investigator 1 Alkermes, Inc. $1,608.75 08/20/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622579
Principal investigator 1 Alkermes, Inc. $1,640.00 07/25/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623032
Principal investigator 1 Alkermes, Inc. $1,667.50 06/23/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615191
Principal investigator 1 Alkermes, Inc. $1,667.50 06/23/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620319
Principal investigator 1 Alkermes, Inc. $1,667.50 06/23/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626420
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,575.00 06/18/2025 Non-covered Recipient Entity
HARMONEX INC
ITI-007-321 No dispute reported 06/30/2026 1242351066
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $399.00 06/05/2025 Non-covered Recipient Entity
HARMONEX INC
A LONG-TERM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF FLEXIBLE-DOSE BREXPIPRAZOLE AS MAINTENANCE TREATMENT IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 1225335923
Principal investigator 1 Alkermes, Inc. $1,116.25 05/21/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208621182
Principal investigator 1 Alkermes, Inc. $1,729.38 05/21/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622886
Principal investigator 1 Alkermes, Inc. $1,216.25 05/16/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622011
Principal investigator 1 Alkermes, Inc. $1,667.50 05/16/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624256
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701588
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701590
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701592
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701594
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701596
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701598
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701600
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701602
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701604
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701606
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701608
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701610
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701612
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701614
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701616
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701618
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701640
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701778
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 05/02/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701780
Principal investigator 1 Alkermes, Inc. $1,685.00 04/23/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613499
Principal investigator 1 Alkermes, Inc. $1,116.25 04/23/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613942
Principal investigator 1 Alkermes, Inc. $1,698.75 04/23/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623856
Principal investigator 1 ABBVIE INC. $10,032.00 04/03/2025 Non-covered Recipient Entity
HARMONEX INC
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202469762
Principal investigator 1 Alkermes, Inc. $1,116.25 04/02/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615811
Principal investigator 1 Alkermes, Inc. $1,156.25 04/02/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618693
Principal investigator 1 Alkermes, Inc. $1,698.75 04/02/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208619157
Principal investigator 1 Alkermes, Inc. $1,685.00 04/02/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623610
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701620
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701622
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701624
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701626
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701628
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701630
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701632
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701634
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701636
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701638
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701642
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701644
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701646
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701648
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701650
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701652
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701654
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701656
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701658
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 03/21/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701660
Principal investigator 1 Alkermes, Inc. $23,719.50 02/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208612837
Principal investigator 1 Alkermes, Inc. $2,362.50 02/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616491
Principal investigator 1 Alkermes, Inc. $1,685.00 02/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616665
Principal investigator 1 Alkermes, Inc. $2,362.50 02/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618189
Principal investigator 1 Alkermes, Inc. $2,358.75 02/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208619871
Principal investigator 1 Alkermes, Inc. $2,362.50 02/24/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626644
Principal investigator 1 Alkermes, Inc. $19,327.00 02/20/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208612811
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701662
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701664
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701666
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701668
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701670
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701672
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701674
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 02/19/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701676
Principal investigator 1 Alkermes, Inc. $1,685.00 01/22/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615533
Principal investigator 1 Alkermes, Inc. $1,685.00 01/22/2025 Non-covered Recipient Entity
HARMONEX, INC.
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620099
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701678
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701680
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701682
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701684
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701686
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701688
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701690
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701692
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701694
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701696
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701698
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701700
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701702
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701704
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701706
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701708
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701710
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701712
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701714
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701716
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701718
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701720
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701722
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701724
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701726
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701728
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701730
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701732
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701734
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701736
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701738
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701740
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701742
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701744
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701746
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701748
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701750
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701752
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701754
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701756
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701758
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701760
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701762
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701764
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701766
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701768
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701770
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701772
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701774
Principal investigator 1 Boehringer Ingelheim International GmbH $1,157.00 01/10/2025 Non-covered Recipient Entity
Harmonex Neurological Science
Real-World Evidence Generation for Bipolar Personality Disorder (BPD),Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) Study / Physician Survey AND Real-World Evidence Generation for Borderline Personality Disorder (BPD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) No dispute reported 06/30/2026 1220701776
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,575.00 01/03/2025 Non-covered Recipient Entity
HARMONEX INC
ITI-007-601 No dispute reported 06/30/2026 1242327996